What: American Society of Nephrology Kidney Week Press Briefing
When: Thursday, November 7, 2019 at 9:45 am ET
Where: Room 208A, Walter E. Washington Convention Center, Washington, DC
Why: Briefing will feature presentations of High-Impact Clinical Trials. Dr. Pascale Lane and Dr. Kelly Hyndman will moderate and provide context and expert commentary on the science presented.
Authors and studies being presented are:
Effect of Angiotensin-Neprilysin Inhibition on Renal Outcomes in Heart Failure with Preserved Ejection Fraction – Finnian R. McCausland
The Dapagliflozin in Heart Failure with Reduced Ejection Fraction Trial (DAPA-HF): Outcomes in Patients with CKD and Effects on Renal Function – Scott D. Solomon
Efficacy and Safety of Difelikefalin in Patients Undergoing Hemodialysis with Pruritus: Results from a Phase 3 Randomized, Controlled Study (KALM-1) – Steven Fishbane
Mycophenolate Mofetil vs. Azathioprine in Kidney Transplant Recipients on Steroid-Free, Low-Dose Cyclosporine Immunosuppression: The ATHENA Trial – Paolo Cravedi
A Phase 2 Randomized, Controlled Study of Obinutuzumab with Mycophenolate and Corticosteroids in Proliferative Lupus Nephritis – Brad H. Rovin
Preventing Early Renal Loss in Diabetes (PERL) Study: Outcome of a 3-Year Trial of Serum Uric Acid Reduction with Allopurinol – Alessandro Doria
Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function and Damage in Type 2 Diabetes – Ian H. de Boer
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #